bispecific therapeutics

Oncology

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

News

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.